Sensei Biotherapeutics, Inc. Stock Price, News & Analysis

Sensei Biotherapeutics (NASDAQ: SNSE) has announced an upcoming presentation of clinical data at the ESMO Congress 2025 in Berlin, Germany. The presentation will focus on results from the Phase 1 dose expansion cohort studying solnerstotug, both as a monotherapy and in combination with Regeneron's PD-1 inhibitor Libtayo® (cemiplimab).

The study specifically examines patients with advanced solid tumors resistant to prior PD-(L)1 therapy. Dr. Kyriakos Papadopoulos from START, San Antonio will present the findings on October 17, 2025 during a mini oral session.

Sensei Biotherapeutics (NASDAQ: SNSE) has announced a 1-for-20 reverse stock split effective June 16, 2025, at 5:00 p.m. Eastern Time. The split aims to maintain Nasdaq Capital Market listing compliance by meeting minimum bid price requirements. Trading under the split-adjusted basis will begin on June 17, 2025, with a new CUSIP number 81728A207. The reverse split will reduce outstanding shares from 25.2 million to approximately 1.3 million, and authorized shares from 250 million to 12.5 million. The company will adjust conversion and exercise prices for outstanding stock options, RSUs, and warrants proportionally. Stockholders will receive cash payments for fractional shares, with Equiniti Trust Company serving as the exchange agent.

Sensei Biotherapeutics (NASDAQ: SNSE) reported Q1 2025 financial results and clinical progress for its cancer therapeutic solnerstotug. The company reported favorable clinical data in PD-(L)1 resistant patients, with response rates nearly three times higher than expected. The Phase 1/2 trial has completed enrollment with 63 total patients, including 10 MSS CRC patients in monotherapy and 53 in the cemiplimab combination arm. Financially, Sensei reported cash position of $34.3 million, with runway into Q2 2026. Q1 2025 showed reduced losses with net loss of $6.9 million compared to $8.0 million in Q1 2024. R&D expenses decreased to $3.7 million from $4.9 million year-over-year, while G&A expenses dropped to $3.5 million from $3.8 million.

Sensei Biotherapeutics (Nasdaq: SNSE), a clinical stage biotechnology company specializing in next-generation cancer therapeutics, has announced its participation in an upcoming industry event. John Celebi, President and CEO, will be a panelist in the New Radiotherapy and Targeted Therapy Approaches discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference. The panel is scheduled for Monday, April 7 at 2:00 p.m. ET.

Sensei Biotherapeutics (NASDAQ: SNSE) reported its full year 2024 financial results and clinical progress for solnerstotug, their conditionally active antibody targeting VISTA. Key clinical highlights include:

In the Phase 1/2 dose expansion study, among 21 evaluable PD-(L)1 resistant tumor patients, the combination therapy showed 14% overall response rate (3x higher than historical rates) and 62% disease control rate. The study achieved target enrollment of 60 patients, with full expansion data expected by year-end 2025.

Financial results show:

• Cash position: $41.3M as of December 31, 2024
• R&D expenses: $18.6M (vs $18.3M in 2023)
• G&A expenses: $13.0M (vs $18.8M in 2023)
• Net loss: $30.2M (vs $34.1M in 2023)

The company expects its current cash runway to extend into Q2 2026.

Sensei Biotherapeutics (NASDAQ: SNSE) has reported promising preliminary results from its Phase 1/2 trial of solnerstotug, a conditionally active antibody targeting VISTA. The drug showed significant clinical activity in PD-(L)1 resistant tumors, achieving a 14% overall response rate - nearly triple the historical rechallenge rates of ≤5%.

Key findings include:

• One durable complete response in Merkel Cell Carcinoma (MCC)
• Two partial responses in MCC and MSI-H Colorectal Cancer patients
• 62% disease control rate among 21 evaluable PD-(L)1 resistant patients
• All patients with tumor shrinkage remain on treatment

The drug demonstrated favorable safety with no dose-limiting toxicities, mostly Grade 1-2 adverse events, and only 7% cases of mild cytokine release syndrome. Subject to capital raising, Sensei plans to initiate Phase 2 studies in Q1 2026.

Sensei Biotherapeutics (Nasdaq: SNSE), a clinical stage biotechnology company specializing in next-generation cancer therapeutics, has announced its participation in Oppenheimer's 35th Annual Healthcare Life Sciences Conference. The company's President and CEO, John Celebi, will deliver a presentation at the virtual event on Tuesday, February 11, 2025, at 10:40 a.m. ET.

Interested parties can access the presentation webcast through the Investors section of Sensei's website. The replay will remain available for approximately 90 days after the event, and registration for the webcast is currently open.

Sensei Biotherapeutics (NASDAQ: SNSE) provided updates on its lead program, solnerstotug (SNS-101), a conditionally active antibody targeting VISTA in cancer treatment. The company has enrolled 45 patients in the dose expansion portion of its Phase 1/2 clinical trial, with full enrollment of approximately 60 patients expected by Q1 2025.

The trial evaluates solnerstotug both as monotherapy and in combination with Libtayo® in patients with advanced solid tumors. Most enrolled 'hot' tumor patients have either progressed on prior anti-PD-1 therapy or are PD-L1 negative. The drug continues to show good tolerability with a best-in-class pharmacokinetic profile, with dose optimization focusing on 3 and 15 mg/kg Q3W levels.

Clinical data update is expected in Q2 2025, including patient follow-up data from dose escalation cohorts. The company maintains cash runway into Q2 2026.

Sensei Biotherapeutics (Nasdaq: SNSE) announced its participation in Citi's 2024 Global Healthcare Conference. The conference will take place from December 3-5 in Miami, FL. As a clinical stage biotechnology company specializing in next-generation cancer therapeutics, Sensei's management team will be present at this significant healthcare industry event.